Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 1;180(11):1531-1533.
doi: 10.1001/jamainternmed.2020.2750.

Representation of Older Adults in Cardiovascular Disease Trials Since the Inclusion Across the Lifespan Policy

Michael G Nanna  1   2 , Sean T Chen  2 , Adam J Nelson  1 , Ann Marie Navar  1   2 , Eric D Peterson  1   2
Affiliations
Review

Representation of Older Adults in Cardiovascular Disease Trials Since the Inclusion Across the Lifespan Policy

Michael G Nanna et al. JAMA Intern Med. .

Abstract

This review compares representation of older adults in interventional cardiovascular disease studies in the US before and after implementation of the National Institutes of Health’s Inclusion Across the Lifespan Policy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Nanna reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Navar reported receiving personal fees from Amgen, AstraZeneca, Janssen, Esperion, Amarin, Sanofi, Regeneron, Novo Nordisk, Novartis, The Medicines Company, and Pfizer and grants from Amgen, Janssen, Amarin, Sanofi, and Regeneron outside the submitted work. Dr Peterson reported receiving grants from Amgen, Sanofi, AstraZeneca, Merck, and Janssen and personal fees from Amgen, AstraZeneca, Merck, Novartis, Pfizer, Janssen, and Sanofi outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Barriers to Representation of Older Adults in Cardiovascular Disease Trials Before and After the Inclusion Across the Lifespan Policy
See this image and copyright information in PMC

Comment in

References

    1. Zulman DM, Sussman JB, Chen X, Cigolle CT, Blaum CS, Hayward RA. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med. 2011;26(7):783-790. doi:10.1007/s11606-010-1629-x - DOI - PMC - PubMed
    1. Sardar MR, Badri M, Prince CT, Seltzer J, Kowey PR. Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA Intern Med. 2014;174(11):1868-1870. doi:10.1001/jamainternmed.2014.4758 - DOI - PubMed
    1. Tinetti ME. The gap between clinical trials and the real world: extrapolating treatment effects from younger to older adults. JAMA Intern Med. 2014;174(3):397-398. doi:10.1001/jamainternmed.2013.13283 - DOI - PubMed
    1. Bernard MA, Clayton JA, Lauer MS. Inclusion across the lifespan: NIH policy for clinical research. JAMA. 2018;320(15):1535-1536. doi:10.1001/jama.2018.12368 - DOI - PubMed
    1. National Institutes of Health Revision: NIH Policy and Guidelines on the Inclusion of Individuals Across the Lifespan as Participants in Research Involving Human Subjects. National Institutes of Health; 2017. Notice NOT-OD-18-116. Accessed March 9, 2020. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-116.html

Publication types